Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07674550
Starting soon Observational

Biological Collection on Emerging Infectious Diseases and Their Treatments

NCT07674550 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2026-06-15
Last updated
2026-06-29

Condition(s) studied

Emerging Infectious Diseases and Their Treatments

Study summary

Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs). Advances in the treatment of cancers, malignant haematological disorders and immune-mediated inflammatory diseases are also contributing to the creation of new infectious risks among immunocompromised patient populations.

The COVID-19 pandemic has shown that structuring research prior to any outbreak is essential for the rapid implementation of responses to the emergence of an EID. The unpredictability of an EID's occurrence necessitates the planning of research projects in advance. A key element in this planning is the development of a collection of biological samples, providing a structured and immediately deployable resource for conducting pathophysiological and therapeutic research aimed at:

* Analyze the biological determinants of the microbe and the resulting infection
* Develop new tools for identification and characterization
* Study the factors (biomarkers/signatures) associated with individual patient susceptibility and response to treatment (personalized medicine)
* Understand the pathophysiology of infection to identify new targets for diagnostic, curative and preventive treatment
* Monitor the efficacy of curative and preventive treatments

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years or over * Patients or individuals who have been exposed, are at risk of exposure, or are at risk of complications if exposed, or who are suspected of having, or are diagnosed with, an infectious disease considered to be emerging or at risk of emerging * Patients receiving, or likely to receive, innovative treatments for the infection (new therapeutic molecules, checkpoint inhibitors, cell therapies, etc.) * Patients or individuals receiving, or likely to receive, vaccines or other preventive therapeutic strategies * Pregnant and breastfeeding women may be included. Exclusion Criteria: \- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)

Primary outcome measure(s)

  • Collection of biological samples and associated data from patients at risk of acquiring, or affected by, emerging or potentially emerging infectious diseases, including those receiving preventive or curative treatment for such infections — through study completion, an average of 1 year
    Prospective collection of all available biological and clinical-biological-imaging data collected during the usual clinical care

Trial sites (1)

FacilityCityRegionStatus
University Hospital Toulouse Toulouse France

More University Hospital, Toulouse trials in France

Intragastric Balloon in Obese Patients With Uncontrolled Asthma Recruiting
Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants Starting soon
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Starting soon
LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly Recruiting
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07674550 on ClinicalTrials.gov ↗ ← All trials in France